Sami Boumahd, Nicolas Piette, Vincent Bonhomme, Grégory Hans
About 30 % of patients scheduled for surgery present with preoperative anemia. The presence of preoperative anemia increases the likelihood of exposure to allogenic blood transfusions, which carries specific complications. Furthermore, and independently of the transfusion risk, it is associated with an increased risk of postoperative morbidity and mortality. It is now recommended to treat preoperative anemia whenever possible. This article summarizes the prognostic implications of preoperative anemia and proposes a diagnostic and therapeutic strategy for the most common clinical situations. Finally, it illustrates how collaboration between primary care and hospital medicine can provide patients with effective and personalized treatment without the need to alter the surgical planning.
{"title":"[Preoperative anemia : a review of its prognostic implications, diagnosis and management].","authors":"Sami Boumahd, Nicolas Piette, Vincent Bonhomme, Grégory Hans","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>About 30 % of patients scheduled for surgery present with preoperative anemia. The presence of preoperative anemia increases the likelihood of exposure to allogenic blood transfusions, which carries specific complications. Furthermore, and independently of the transfusion risk, it is associated with an increased risk of postoperative morbidity and mortality. It is now recommended to treat preoperative anemia whenever possible. This article summarizes the prognostic implications of preoperative anemia and proposes a diagnostic and therapeutic strategy for the most common clinical situations. Finally, it illustrates how collaboration between primary care and hospital medicine can provide patients with effective and personalized treatment without the need to alter the surgical planning.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"79 12","pages":"766-770"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142857503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tirzepatide is a unimolecular dual agonist of both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, which has been developed as once-weekly injection first for the treatment of type 2 diabetes (T2DM), then for the treatment of obesity. Because of the complementarity of action of the two incretins, tirzepatide showed, in a dose-dependent manner (5, 10 and 15 mg), a better efficacy (greater reduction in HbA1c and body weight) compared with placebo, semaglutide 1 mg, basal insulin and preprandial boluses of insulin lispro in six studies of the SURPASS programme. In the SURMOUNT programme, tirzepatide showed a marked reduction in body weight, never reached before with a drug, among people with obesity or overweight associated with complications linked to excess weight. Such weight loss was accompanied by an improvement of comorbidities (as sleep apnea syndrome) and cardiovascular risk factors. Two large cardiovascular outcome trials are ongoing in patients with T2DM (SURPASS-CVOT) and in patients with obesity (SURMOUNT-MMO).
{"title":"[Tirzepatide : overview of clinical studies SURPASS in type 2 diabetes and SURMOUNT in obesity].","authors":"André Scheen","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Tirzepatide is a unimolecular dual agonist of both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, which has been developed as once-weekly injection first for the treatment of type 2 diabetes (T2DM), then for the treatment of obesity. Because of the complementarity of action of the two incretins, tirzepatide showed, in a dose-dependent manner (5, 10 and 15 mg), a better efficacy (greater reduction in HbA1c and body weight) compared with placebo, semaglutide 1 mg, basal insulin and preprandial boluses of insulin lispro in six studies of the SURPASS programme. In the SURMOUNT programme, tirzepatide showed a marked reduction in body weight, never reached before with a drug, among people with obesity or overweight associated with complications linked to excess weight. Such weight loss was accompanied by an improvement of comorbidities (as sleep apnea syndrome) and cardiovascular risk factors. Two large cardiovascular outcome trials are ongoing in patients with T2DM (SURPASS-CVOT) and in patients with obesity (SURMOUNT-MMO).</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"79 12","pages":"812-820"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142857509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hernan Valdes-Socin, Brieuc Sautois, Maxime Sempels
We report the case of a 39-year-old patient who complains about loss of libido and erectile dysfunction. Hormonal diagnosis revealed hypergonadotropic hypogonadism suggesting a primitive testicular cause. Testicular examination, testicular ultrasounds and abdomen-pelvis CT scan made it possible to suspect a right testicular tumor. A stage I seminoma was confirmed at orchiectomy. Testicular cancer is the most common cancer in men before the age of 35. Most testicular tumors initially present with a scrotal mass: a testicular tumor should not be ignored in a patient with hypergonadotropic hypogonadism.
{"title":"[Testicular seminoma revealed by hypergonadotropic hypogonadism].","authors":"Hernan Valdes-Socin, Brieuc Sautois, Maxime Sempels","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>We report the case of a 39-year-old patient who complains about loss of libido and erectile dysfunction. Hormonal diagnosis revealed hypergonadotropic hypogonadism suggesting a primitive testicular cause. Testicular examination, testicular ultrasounds and abdomen-pelvis CT scan made it possible to suspect a right testicular tumor. A stage I seminoma was confirmed at orchiectomy. Testicular cancer is the most common cancer in men before the age of 35. Most testicular tumors initially present with a scrotal mass: a testicular tumor should not be ignored in a patient with hypergonadotropic hypogonadism.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"79 12","pages":"751-754"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142857505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Matthieu Thimmesch, Jessica Meurrens, Aline Tataris, Jessica Pirson, Anne Tamigniau
The chloride (Cl-) sweat test remains the reference test in the diagnosis of cystic fibrosis, allowing direct assessment of CFTR (Cystic Fibrosis Transmembrane conductance Regulator) channel function. Under highly effective modulators such as the combination of Elexacaftor, Tezacaftor and Ivacaftor (ETI), the Cl- level in sweat significantly improves, as shown in our cohort of patients when ETI was introduced. In addition to its role in the diagnosis of the disease, the sweat test is also important for individual clinical trials (n-of-1) in patients not eligible for ETI and for newborn screening for cystic fibrosis.
氯化物(Cl-)汗液测试仍是诊断囊性纤维化的参考测试,可直接评估 CFTR(囊性纤维化跨膜传导调节器)通道的功能。在高效调节剂(如 Elexacaftor、Tezacaftor 和 Ivacaftor 的组合(ETI))的作用下,汗液中的 Cl- 水平会显著改善,正如我们的患者队列在引入 ETI 后所显示的那样。除了在疾病诊断中的作用外,汗液检测对于不符合 ETI 条件的患者的个体临床试验(n-of-1)和新生儿囊性纤维化筛查也很重要。
{"title":"[Sweat test evolution in cystic fibrosis patients treated with Elexacaftor/Tezacaftor/Ivacaftor].","authors":"Matthieu Thimmesch, Jessica Meurrens, Aline Tataris, Jessica Pirson, Anne Tamigniau","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The chloride (Cl-) sweat test remains the reference test in the diagnosis of cystic fibrosis, allowing direct assessment of CFTR (Cystic Fibrosis Transmembrane conductance Regulator) channel function. Under highly effective modulators such as the combination of Elexacaftor, Tezacaftor and Ivacaftor (ETI), the Cl- level in sweat significantly improves, as shown in our cohort of patients when ETI was introduced. In addition to its role in the diagnosis of the disease, the sweat test is also important for individual clinical trials (n-of-1) in patients not eligible for ETI and for newborn screening for cystic fibrosis.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"79 11","pages":"716-718"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142640510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Thibaut Lejeune, Guillaume Résimont, Bernard Dubois, Alexandre Ghuysen, Bernard Lambermont, Étienne Cavalier, François Jouret, Pierre Delanaye
Hyperkalemia is an electrolyte disorder defined as a plasma potassium concentration greater than 5 mmol/L. Plasma potassium represents approximately 2 % of the total body potassium, and its regulation depends mainly on renal excretion and transcellular shifts. Various pathologies can alter potassium homeostasis and lead to acute or chronic hyperkalemia. The rate of change in plasma potassium concentration is critical because the faster it occurs, the faster life-threatening symptoms develop. Therefore, acute hyperkalemia should be urgently treated. There is no «threshold» value defining the severity of the situation, but the electrocardiographic changes appear to be valuable indicators of severity. Several medical associations have issued recommendations regarding the emergency management of hyperkalemia, but there is no scientific consensus. In this article, we summarize the current knowledge and propose a practical management algorithm for the management of acute hyperkalemia.
{"title":"[Acute hyperkalemia management].","authors":"Thibaut Lejeune, Guillaume Résimont, Bernard Dubois, Alexandre Ghuysen, Bernard Lambermont, Étienne Cavalier, François Jouret, Pierre Delanaye","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Hyperkalemia is an electrolyte disorder defined as a plasma potassium concentration greater than 5 mmol/L. Plasma potassium represents approximately 2 % of the total body potassium, and its regulation depends mainly on renal excretion and transcellular shifts. Various pathologies can alter potassium homeostasis and lead to acute or chronic hyperkalemia. The rate of change in plasma potassium concentration is critical because the faster it occurs, the faster life-threatening symptoms develop. Therefore, acute hyperkalemia should be urgently treated. There is no «threshold» value defining the severity of the situation, but the electrocardiographic changes appear to be valuable indicators of severity. Several medical associations have issued recommendations regarding the emergency management of hyperkalemia, but there is no scientific consensus. In this article, we summarize the current knowledge and propose a practical management algorithm for the management of acute hyperkalemia.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"79 11","pages":"687-695"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142640501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marie Delvenne, Valérie Bonhivers, Laurence Seidel, Philippe Delvenne, Bernard Duysinx, Guy Jerusalem, Renaud Louis
This retrospective study including 93 patients who presented a new diagnosis of lung cancer at the University Hospital of Liege between January 2023 and April 2023 analyzed the prevalence of smoking cessation following the diagnosis announcement. It was also investigated whether certain factors influenced this rate (stage, histology, type of treatment received, tobacco monitoring,…) and whether the impact of this smoking cessation influenced the progression of the disease and the response to oncological treatments. The results show that 34.8 % of active smokers at diagnosis experienced smoking cessation at 6 months and 32.6 % at 1 year. This success rate of more than 30 % at 1 year is considerably higher than the success rates observed in individuals who attempt to obtain smoking cessation spontaneously and independently, outside of a cancer diagnosis (3-5 %). However, it remains low if one consider that smoking cessation is an important factor for increasing the survival rate for this type of cancer. It should be noted that, among the 51 smokers still active, 42 (82.4 %) did not consult a tobacco specialist. Smoking cessation support should in fact be offered to patients diagnosed with lung cancer more systematically and as early as possible in order to optimize the effectiveness of treatments and to increase the chances of survival.
{"title":"[Retrospective study on smoking in lung cancer at the University Hospital of Liège].","authors":"Marie Delvenne, Valérie Bonhivers, Laurence Seidel, Philippe Delvenne, Bernard Duysinx, Guy Jerusalem, Renaud Louis","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This retrospective study including 93 patients who presented a new diagnosis of lung cancer at the University Hospital of Liege between January 2023 and April 2023 analyzed the prevalence of smoking cessation following the diagnosis announcement. It was also investigated whether certain factors influenced this rate (stage, histology, type of treatment received, tobacco monitoring,…) and whether the impact of this smoking cessation influenced the progression of the disease and the response to oncological treatments. The results show that 34.8 % of active smokers at diagnosis experienced smoking cessation at 6 months and 32.6 % at 1 year. This success rate of more than 30 % at 1 year is considerably higher than the success rates observed in individuals who attempt to obtain smoking cessation spontaneously and independently, outside of a cancer diagnosis (3-5 %). However, it remains low if one consider that smoking cessation is an important factor for increasing the survival rate for this type of cancer. It should be noted that, among the 51 smokers still active, 42 (82.4 %) did not consult a tobacco specialist. Smoking cessation support should in fact be offered to patients diagnosed with lung cancer more systematically and as early as possible in order to optimize the effectiveness of treatments and to increase the chances of survival.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"79 11","pages":"701-710"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142640508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In the course of several neurodegenerative conditions, the presence of a sensory alteration, even before the appearance of cognitive disorders or complaints concerning autonomy, can potentially lead to earlier diagnosis and more efficient management of these complex patients. The mechanisms underlying the association between sensory impairment and the risk of progression to dementia are increasingly better understood and should ultimately improve the accuracy of the diagnosis process for the most common neurodegenerative conditions, but also participate in the differential diagnosis between these conditions. Finally, early management of these sensory impairments offers a relatively easy way to modify patient's progression by delaying the onset of several symptoms during the progression towards a dementia syndrome.
{"title":"[Senses and dementia : sensory loss and dementia risk].","authors":"Pauline Smeets, Justine Laverdeur, Zayd Jedidi, Haroun Jedidi, Frédérique Depierreux","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In the course of several neurodegenerative conditions, the presence of a sensory alteration, even before the appearance of cognitive disorders or complaints concerning autonomy, can potentially lead to earlier diagnosis and more efficient management of these complex patients. The mechanisms underlying the association between sensory impairment and the risk of progression to dementia are increasingly better understood and should ultimately improve the accuracy of the diagnosis process for the most common neurodegenerative conditions, but also participate in the differential diagnosis between these conditions. Finally, early management of these sensory impairments offers a relatively easy way to modify patient's progression by delaying the onset of several symptoms during the progression towards a dementia syndrome.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"79 11","pages":"719-723"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142640509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In a first article we highlighted the importance of serious gaming in physical medicine and in rehabilitation. In this second article on the same topic, we discuss the potential impact of serious gaming in the field of mental health. The technical aspects, advantages and disadvantages, limits and pitfalls are rapidly overviewed in different areas such as addiction, anxiety, autism, depression, schizophrenia, attention disorders, post-traumatic stress syndrome, obsessive compulsive disorders and memory disorders. It is noteworthy that the American Food and Drug Administration awarded its precious label for the very first time to a serious game used for attention-deficit hyperactivity disorder.
{"title":"[Health is a serious matter : so let's play ! Part 2 : an overview of «serious gaming» in mental health].","authors":"Philippe Coucke","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In a first article we highlighted the importance of serious gaming in physical medicine and in rehabilitation. In this second article on the same topic, we discuss the potential impact of serious gaming in the field of mental health. The technical aspects, advantages and disadvantages, limits and pitfalls are rapidly overviewed in different areas such as addiction, anxiety, autism, depression, schizophrenia, attention disorders, post-traumatic stress syndrome, obsessive compulsive disorders and memory disorders. It is noteworthy that the American Food and Drug Administration awarded its precious label for the very first time to a serious game used for attention-deficit hyperactivity disorder.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"79 11","pages":"731-738"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142640505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Elie Minga Lowampa, Jean-Paul Lavigne, Manuel Azevedo Mendes, Marc Gilbert Lagny, Vincent Tchana-Sato
The efficiency of minimally invasive aortic valve surgery via right anterior thoracotomy is now well established. As far as coronary artery bypass graft surgery is concerned, many specialized centres are performing minimally invasive procedures with a left mini-thoracotomy either off-pump or on-pump. Multivessel operation is feasible. Up to date, only few authors described both procedures (coronary bypass graft surgery and valve surgery) in the same patient with a minimally invasive approach. We report a case of a female patient undergoing a single arterial coronary bypass surgery on the left anterior descending artery combined with an aortic valve replacement through bilateral anterior mini-thoracotomies.
{"title":"[Combined single coronary artery by-pass graft surgery and aortic valve replacement through bilateral mini-thoracotomies].","authors":"Elie Minga Lowampa, Jean-Paul Lavigne, Manuel Azevedo Mendes, Marc Gilbert Lagny, Vincent Tchana-Sato","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The efficiency of minimally invasive aortic valve surgery via right anterior thoracotomy is now well established. As far as coronary artery bypass graft surgery is concerned, many specialized centres are performing minimally invasive procedures with a left mini-thoracotomy either off-pump or on-pump. Multivessel operation is feasible. Up to date, only few authors described both procedures (coronary bypass graft surgery and valve surgery) in the same patient with a minimally invasive approach. We report a case of a female patient undergoing a single arterial coronary bypass surgery on the left anterior descending artery combined with an aortic valve replacement through bilateral anterior mini-thoracotomies.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"79 11","pages":"696-700"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142640503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Charlotte Chabot, Jean-François Kaux, Pascal Piret, Gilles Colin
Tendinopathies are disorders of the tendons, often caused by overuse. They often affect athletes and manual workers and represent a major medical challenge. Current treatments are numerous, including physiotherapy, anti-inflammatory drugs and sometimes surgery. However, because of sometimes disappointing results with these treatments, radiotherapy is emerging as an alternative. Used for its anti-inflammatory properties, it could specifically target the pathological processes of tendinopathy. At low doses, radiotherapy shows beneficial effects on inflammation, neovascularization and tissue regeneration. It thus contributes to tendon repair. Clinical studies suggest that it can relieve symptoms, improve quality of life and often avoid surgery. However, concerns remain about potential risks, particularly the risk of radiation-induced cancer. Despite this small risk, the benefits of radiation therapy make it a promising option.
{"title":"[The benefits of radiotherapy in the treatment of tendinopathies].","authors":"Charlotte Chabot, Jean-François Kaux, Pascal Piret, Gilles Colin","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Tendinopathies are disorders of the tendons, often caused by overuse. They often affect athletes and manual workers and represent a major medical challenge. Current treatments are numerous, including physiotherapy, anti-inflammatory drugs and sometimes surgery. However, because of sometimes disappointing results with these treatments, radiotherapy is emerging as an alternative. Used for its anti-inflammatory properties, it could specifically target the pathological processes of tendinopathy. At low doses, radiotherapy shows beneficial effects on inflammation, neovascularization and tissue regeneration. It thus contributes to tendon repair. Clinical studies suggest that it can relieve symptoms, improve quality of life and often avoid surgery. However, concerns remain about potential risks, particularly the risk of radiation-induced cancer. Despite this small risk, the benefits of radiation therapy make it a promising option.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"79 11","pages":"711-715"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142640511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}